Objective-The main objective of this study is to define the mechanisms by which mitochondria control vascular smooth muscle cell (VSMC) migration and impact neointimal hyperplasia. Approach and Results-The multifunctional CaMKII (Ca 2+ /calmodulin-dependent kinase II) in the mitochondrial matrix of VSMC drove a feed-forward circuit with the mitochondrial Ca 2+ uniporter (MCU) to promote matrix Ca 2+ influx. MCU was necessary for the activation of mitochondrial CaMKII (mtCaMKII), whereas mtCaMKII phosphorylated MCU at the regulatory site S92 that promotes Ca 2+ entry. mtCaMKII was necessary and sufficient for platelet-derived growth factor-induced mitochondrial Ca 2+ uptake. This effect was dependent on MCU. mtCaMKII and MCU inhibition abrogated VSMC migration and mitochondrial translocation to the leading edge. Overexpression of wild-type MCU, but not MCU S92A, mutant in MCU −/− VSMC rescued migration and mitochondrial mobility. Inhibition of microtubule, but not of actin assembly, blocked mitochondrial mobility. The outer mitochondrial membrane GTPase Miro-1 promotes mitochondrial mobility via microtubule transport but arrests it in subcellular domains of high Ca 2+ concentrations. In Miro-1 −/− VSMC, mitochondrial mobility and VSMC migration were abolished, and overexpression of mtCaMKII or a CaMKII inhibitory peptide in mitochondria (mtCaMKIIN) had no effect. Consistently, inhibition of mtCaMKII increased and prolonged cytosolic Ca 2+ transients. mtCaMKII inhibition diminished phosphorylation of focal adhesion kinase and myosin light chain, leading to reduced focal adhesion turnover and cytoskeletal remodeling. In a transgenic model of selective mitochondrial CaMKII inhibition in VSMC, neointimal hyperplasia was significantly reduced after vascular injury. Conclusions-These findings identify mitochondrial CaMKII as a key regulator of mitochondrial Ca 2+ uptake via MCU, thereby controlling mitochondrial translocation and VSMC migration after vascular injury. Visual Overview-An online visual overview is available for this article.
A therosclerotic vascular disease is the leading cause of mortality in the industrialized world and commonly treated by percutaneous balloon angioplasty and stent placement. However, even with contemporary drug-eluting stents, restenosis via neointimal hyperplasia occurs after 10% to 30% of percutaneous arterial interventions. 1 Neointimal hyperplasia develops from excessive vascular smooth muscle cell (VSMC) migration and proliferation from the medial layer to the arterial lumen, narrowing the luminal diameter leading to decreased blood flow and recurrence of anginal symptoms. 2 Thus, neointimal hyperplasia remains a significant clinical problem in patients with vascular disease.
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Previous studies have supported that mitochondrial physiology affects VSMC phenotypes and vascular disease, such as neointimal hyperplasia, 3, 4 atherosclerosis, 5 and hypertension. 6 These studies primarily interrogated well-established concepts in VSMC phenotypes in vascular disease, such as mitochondrial reactive oxygen species (ROS) production and mitochondrial fission and fusion. For example, neointimal hyperplasia was blocked by delivery of mitochondrial manganese superoxide dismutase to VSMC. 3 Because mitochondria undergo dynamic fission and fusion during the cell cycle, inhibition of mitochondrial fission as anticipated decreased neointimal hyperplasia and VSMC proliferation. 4 Although these studies implicate that mitochondria affect vascular function and disease, a detailed mechanistic understanding of how intramitochondrial events alter VSMC phenotypes remains elusive.
Recent evidence in cancer and epithelial cells has suggested that mitochondrial translocation to the leading edge is necessary to support cell mobility and invasiveness. [7] [8] [9] [10] At the leading edge, mitochondria localize to the vicinity of focal adhesions (FAs) 11 and support local energy production, 7 necessary for FA turnover and cytoskeletal remodeling. Along with providing energy for VSMC, mitochondria act as major Ca 2+ buffering organelles. 12, 13 Mitochondrial Ca 2+ influx is primarily controlled by mitochondrial Ca 2+ uniporter (MCU), which resides in the inner mitochondrial membrane. MCU activity is modulated by multiple regulators, including MICU1 (mitochondrial Ca 2+ uptake 1) and potentially multifunctional CaMKII (Ca 2+ /calmodulin-dependent kinase II). 14, 15 In cancer cells, MCU inhibition perturbs cell migration. 16 For example, studies in breast cancer 17 and cervical cancer 18 cells demonstrated that migratory capacity directly correlates with the expression of MCU or its regulator MICU1. The mechanisms by which MCU inhibition impairs migration remain unknown. Although incompletely studied in VSMC, data in neurons and cardiac myoblasts suggest that mitochondrial mobility is reduced when local Ca 2+ concentrations are high. 19 Therefore, abrogation of MCU activity may lead to local increase in Ca 2+ concentrations in the vicinity of MCU-deficient mitochondria and thereby decrease cell migration via arresting mitochondrial mobility.
Emerging studies have suggested that CaMKII, a coordinator of Ca 2+ handling in multiple cell types, resides within the mitochondrial matrix of cardiac myocytes 20 and lung epithelial cells. 21 Mitochondrial CaMKII has been suggested to regulate MCU in cardiomyocytes, although the data are controversial. 20, 22, 23 Herein, we test the hypothesis that CaMKII in mitochondria of VSMC controls mitochondrial Ca 2+ uptake and thereby mitochondrial mobility and MCU-dependent VSMC migration, ultimately contributing to neointimal hyperplasia.
Materials and Methods

Materials
The detailed usage of materials and antibodies are included in the online-only Data Supplement.
Mice
All protocols were approved by the University of Iowa Institutional Animal Care and Use Committee and in compliance with the standards for the care and use of laboratory animals of the Institute of Laboratory Animal Resource, National Academy of Science. Mice were maintained in the University of Iowa Animal Facility and treated in accordance with Institutional Animal Care and Use Committee guidelines (PHS Animal Welfare Assurance, A3021-01).
Mice with tamoxifen-inducible Cre recombinase (driven by the SMMHC [smooth muscle myosin heavy chain] promoter) on a C57BL/6 background were used (SM-Cre). 24 These mice carry the Cre gene on the Y chromosome; hence, only male mice were used. Hemagglutinin-tagged mtCaMKIIN mice (mitochondrially targeted peptide inhibitor of CaMKII) were generated as previously described.
21 Double-transgenic mice with VSMC-specific expression of mtCaMKIIN (SM-mtCaMKIIN mice) were generated by crossing SM-Cre mice with hemagglutinin-tagged mtCaMKIIN mice, as diagrammed in Figure XA in the online-only Data Supplement. All mice were genotyped as we previously described. 21 All studies used tamoxifen-treated SM-Cre mice as littermate controls (wild type [WT] ).
Smooth muscle-specific expression of mtCaMKIIN was induced in 6-to 8-week-old male mice via injection of tamoxifen (20 mg/ mL, IP, for 5 days). Recombination was verified by detection of the hemagglutinin tag in aortic lysates by immunoblot and by immunofluorescence in 10-μm frozen carotid sections. Sections were imaged using a Zeiss LSM 510 confocal microscope. MCU −/− mice in CD1 background were a kind gift of Dr Toren Finkel (National Institutes of Health), Miro-1 fl/fl mice were graciously provided by Dr Janet Shaw (University of Utah). Information on strains and sources are provided in the online-only Data Supplement.
Vascular Smooth Muscle Cell Culture
Primary VSMCs were isolated from aortas and cultured in DMEM (Gibco; #11885-092) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, 8 mmol/L HEPES, MEM (minimum essential medium) vitamins, and nonessential amino acids at 37°C in a humidified 95% air and 5% CO 2 incubator. 25 VSMC at passages 4 to 10 were used for all experiments.
Adenoviral Transduction
VSMCs were incubated with adenoviruses expressing mtCaMKIIN, mtGFP (mitochondrial green fluorescent protein), or control at a multiplicity of infection of 50 in serum-free media overnight. Subsequent experiments were conducted 48 to 72 hours after adenoviral transduction as described previously. 21 Miro-1 −/− were generated by infecting VSMC from Miro fl/fl mice with adenovirus expressing Cre recombinase at a multiplicity of infection of 10.
26 Deletion of Miro-1 was confirmed 72 hours after infection by immunoblot.
Isolation of Mitochondrial Fractions and Mitoplasts
Cleaned, segmented mouse aortas or cultured VSMC were suspended in MSE (5 mmol/L 3-(N-morpholino)propanesulfonic acid, 70 mmol/L sucrose, 2 mmol/L ethylene glycol-bis-(β-aminoethyl ether)-N,N′-tetraacetic acid, 220 mmol/L mannitol, pH 7.2, with KOH) on ice followed by homogenization by mortar and pestle. Nuclei and unbroken cells were pelleted by centrifugation at 600g for 10 minutes. Then, centrifugation of the supernatant at 8500g for 20 minutes separated crude mitochondrial from cytosolic fractions. The mitochondrial pellet was resuspended in MSE with protease inhibitors. For mitoplast preparations, crude mitochondria were digested in 20 nmol/L Proteinase K in MSE for 5 minutes on ice. The reaction was stopped by adding PMSF (phenylmethylsulfonyl fluoride; 1 mmol/L), and mitoplasts were pelleted at 10 000g for 10 minutes and resuspended in MSE with protease inhibitors.
Immunoblotting
Immunoblotting experiments were performed following the general protocol for Western blotting by BioRad and detailed protocol 
Determination of Mitochondrial Ca
2+
Ratiometric Ca 2+ measurements in mitochondria were performed in VSMC after transduction with adenovirus expressing mtPericam (mitochondrial Pericam; Ad-mtPericam). 27 Pericam ratiometric fluorescent imaging with the Leica SP8 STED imaging system was used to determine fluorescence signal intensity, with an excitation at 405 nm/480 nm and acquisition at 510 nm. Real-time Pericam fluorescence ratios were recorded after addition of platelet-derived growth factor (PDGF). Peak amplitude (R) was calculated by subtracting the baseline fluorescence ratio from the highest fluorescence ratio. The area under the curve from baseline was determined using GraphPad Prism. Summary data represent the average difference in basal and peak mitochondrial [Ca 2+ ].
The o-Cresolphthalein conjugation colorimetric plate assay was used to measure Ca 2+ concentration of isolated mitochondria from thoracic aortas or cultured VSMC. Mitochondrial Ca 2+ was assessed per the manufacturer's protocol (Cayman Scientific) and normalized to total mitochondrial protein concentration.
Determination of Cytosolic Ca 2+ Transients
Cells were loaded with 2 µmol/L Fura-2 acetoxymethyl ester Ca 2+ -free Hanks balanced salt solution for 20 minutes at 25°C, then washed with Ca 2+ -containing Hanks balanced salt solution at 37°C for 20 minutes. Cells were excited alternatively at 340 and 380 nm. Fluorescence signal intensity was acquired at 510 nm. Realtime shifts in Fura-2 acetoxymethyl ester fluorescence ratio were recorded as PDGF was acutely added using Olympus IX81 Inverted Light Microscope. Peak amplitude (R) was calculated by subtracting the baseline fluorescence ratio from the highest fluorescence ratio. Summary data were calculated using GraphPad Prism.
Migration Assays
Boyden chamber and traditional scratch wound assays were performed as previously described and detailed in the online-only Data Supplement. 28 To perform high-throughput migration assays, VSMC were grown to confluence in a Black, Clear Bottom, Tissue Culture 96-Well with Lid (Perkin Elmer #6005550). Wounding was performed by inserting a conical 96-well PCR plate and scraping to create a cellfree zone. Cells were washed with DMEM and treated in DMEM containing PDGF or vehicle control. Images were taken at ×10 at 0 to 48 hours after injury using the Perkin Elmer Operetta High-Content Imaging System by Digital Phase Contrast. Semiautomated analysis was performed using Image J as detailed in Figure III in the onlineonly Data Supplement. Each condition was performed and analyzed in quadruplicate for each independent experiment.
Quantification of Mitochondrial Distribution
To visualize mitochondrial distribution in migrating cells, VSMCs were simultaneously infected with Ad-mtGFP and Ad-control or Ad-mtCaMKIIN. Cells were subject to a scratch wound assay and allowed to migrate in DMEM/10% fetal bovine serum and PDGF for indicated time points. Inhibitors for mitochondria Ca 2+ (Ru360, 1 µmol/L), mitochondrial ROS (mitoTEMPO [mitochondrial reactive oxygen species scavenger], 10 µmol/L), actin polymerization (Cytochalasin D, 0.1 nmol/L), and microtubules (Nocodazole, 1 µmol/L) were given for the duration of migration. For some experiments, VSMC with Nocodazole were washed and left in DMEM/10% fetal bovine serum 2 hours before fixation to allow microtubule repolymerization. VSMCs were then fixed and stained with phalloidin-568. Images were acquired using a Zeiss 510 confocal microscope with a ×40 objective. Mitochondrial distribution was quantified using National Institutes of Health ImageJ by line scan of mitochondria from the nucleus to the leading edge and by region of interest at the leading edge as outlined in detail in Figure V in the online-only Data Supplement. For both methods, data are expressed as percent of mitochondria in the leading edge area or segment. The image analysis was performed independently by 2 scientists who were blinded to the treatment group.
FA Immunostaining and Analysis
VSMC infected with Ad-control or Ad-mtCaMKIIN were grown to confluence on glass coverslips. A scratch wound assay was performed with PDGF. After 6 hours, cells were washed and fixed in 4% paraformaldehyde, then subject to the staining protocol described in the online-only Data Supplement. Cells were stained with antivinculin primary antibody and phalloidin-568. Images were acquired using the Zeiss LSM 510 confocal microscope. Confocal images were thresholded equally across experiments by ImageJ. Region of interest was selected at the leading edge of every cell, and Analyze Particles function was used to identify and measure all FA.
FA Turnover
VSMCs were nucleofected with GFP-Vinculin plasmid. Images of labeled FA in VSMC were taken after addition of DMEM/10% fetal bovine serum containing PDGF every 15 minutes for a total of 90 minutes. Imaging was performed using the custom-built Nikon BX-81 microscope at ×40 objective. Images were automatically thesholded by CellProfiler, and FAs were identified by Primary Objects function. The first image (green) and last image (red) were pseudocolored and overlayed in CellProfiler. Colocalization of green and red signal of FA at times 0 minutes and 90 minutes was expressed by Mander coefficient.
Carotid Injury Model
Male mice (10-12 weeks old) were subject to carotid injury by endothelial denudation using a resin-bead-coated suture as described in the online-only Data Supplement. 29 At 28 days after injury, all animals were anesthetized and perfused with PBS followed by 4% paraformaldehyde for 3 minutes. The carotid arteries were excised and paraffin embedded. Carotid artery cross-sections (5 μm) were obtained at 50-μm intervals from the carotid bifurcation site for up to 500 µm and stained by Verhoeff Van Gieson. Luminal and intimal areas were determined by tracing the circumference of the internal elastic lamina and the luminal area using National Institutes of Health Image J. The neointimal area was calculated by subtracting the luminal area from the internal elastic lamina area.
Nucleofection
Cells were nucleofected, following manufacturer's protocol (Lonza #VPI-1004). Briefly, 600 000 cells were nucleofected in the presence of 5-µg plasmid DNA and plated onto 3-cm glass coverslip dishes. For FA turnover assays, VSMCs were infected with either Ad-mtCaMKIIN or Ad-Control the next day and allowed to express for 48 hours.
Statistical Analyses
Data are expressed as mean±SEM and analyzed with GraphPad Prism 7.0 software. All data sets were analyzed for normality and equal variance. Kruskall-Wallis test with Dunn post hoc test was used for data sets where normal distribution could not be assumed. Two-tailed unpaired Student t test and 1-way ANOVA followed by Tukey multiple comparison test were used for data sets with normal distribution. Twoway ANOVA followed by Tukey multiple comparison test was used for grouped data sets. A P value <0.05 was considered significant.
Results
CaMKII Is Present and Active in Mitochondria of VSMC
We first established that CaMKII is present in mitochondria of VSMC. We detected CaMKII in whole mitochondria and in mitoplasts, mitochondrial preparations that contain only the matrix and inner mitochondrial membrane ( Figure 1A ). Next, we tested whether CaMKII in mitochondria is activated by PDGF, a well-established agonist in VSMC migration and neointimal hyperplasia. 30 /calmodulin-dependent kinase II) regulates a feed-forward circuit promoting mitochondrial Ca 2+ uptake. A, Representative immunoblot and summary data for CaMKII in mitochondrial (mito) and cytosolic (cyto) fractions and mitoplasts from vascular smooth muscle cell (VSMC). Mitoplasts (inner mitochondrial membrane and matrix) were generated by digestion of mitochondrial fractions with Proteinase K. GAPDH: cytosolic marker; Cox IV: marker of inner mitochondrial membrane; Drp-1: marker of outer mitochondrial membrane. Data quantified as intensity of CaMKII to total amount of protein by BCA (bicinchoninic acid) protein assay (n=4 independent experiments), *P<0.05 vs cytosolic fraction by Kruskall-Wallis. B, Immunoblot for active (phosphorylated, pCaMKII) and total CaMKII in whole-cell lysate and mitoplast fractions of VSMC from MCU −/− (mitochondrial Ca 2+ uniporter double knockout) or wild-type (WT) mice before or after treatment with platelet-derived growth factor (PDGF; 20 ng/mL) for 15 min after serum starvation (serum-free [SF]; n=5 independent experiments). C, Immunoblot for pCaMKII in mitoplast fractions of MCU −/− VSMC after transfection of WT MCU or MCU mutant Ser92 to Ala (S92A) or control and in mitoplasts of WT VSMC, treated as in B (n=5 independent experiments). D, Active (phosphorylated, pMCU, at S92) and total MCU in mitochondrial fractions from VSMC expressing mtCaMKIIN (mitochondrially targeted peptide inhibitor of CaMKII) or control. COX IV: loading control (n=5 independent experiments). at S92, a highly conserved site on the N-terminal domain of MCU, is essential for mitochondrial Ca 2+ uptake. 15 Thus, we overexpressed WT MCU and a mutant of MCU that cannot be phosphorylated at S92 (S92A) in MCU −/− VSMC ( Figure 1C ). Whereas WT MCU expression restored the phosphorylation of CaMKII, this effect was absent with mutant MCU. Of note, we confirmed that expression of MCU WT, but not of the MCU S92A, mutant in MCU −/− markedly augmented mitochondrial Ca 2+ uptake (data not shown). These data suggest that Ca 2+ influx via MCU is necessary and sufficient for CaMKII activation in mitoplast of VSMC.
Studies in other cell types have suggested that mtCaM-KII phosphorylates MCU at S92 although direct evidence is currently missing. 15 To test the effects of mtCaMKII, we developed a model of mitochondrial CaMKII inhibition by adenoviral delivery of CaMKIIN, a specific peptide that blocks substrate binding to all CaMKII isoforms. 31 A COX8 (cytochrome C oxidase subunit 8) mitochondrial targeting sequence was used to target CaMKIIN to the mitochondrial matrix (mtCaMKIIN). In immunoblots, we confirmed mtCaM-KIIN expression in mitoplasts, with minimal detection in the cytosol ( Figure IB and IC in the online-only Data Supplement). Using immunoblots for activated ERK1/2, a bona fide cytosolic CaMKII signaling target, 30, 32 we excluded additional cytosolic effects of mtCaMKIIN ( Figure ID in the online-only Data Supplement). To provide direct evidence that mtCaMKII regulates MCU phosphorylation, we used an antibody that specifically detects phosphorylation of S92 on MCU ( Figure IE in the online-only Data Supplement). In isolated mitochondria of WT cells, PDGF induced phosphorylation of MCU, which was abrogated with mtCaMKIIN expression at baseline and after PDGF ( Figure 1D ). Taken together with the data demonstrating that MCU is necessary for mtCaMKII activation, our findings support a feed-forward circuit by which mitochondrial Ca 2+ uptake via MCU activates mtCaMKII that phosphorylates MCU at S92 and further augments mitochondrial Ca 2+ influx. Therefore, we sought to confirm that mtCaMKII inhibition decreases mitochondrial Ca 2+ uptake using the ratiometric mitochondria-targeted Ca 2+ indicator protein Pericam (mtPericam). 33 PDGF induced mitochondrial Ca 2+ uptake, and mtCaMKIIN significantly blunted the increase in Ca 2+ after PDGF treatment ( Figure 1E) . Moreover, the peak amplitude of the Ca 2+ signal and the area under the curve were reduced (area under the curve, Figure 1E ). Accordingly, we observed significantly lower mitochondrial Ca 2+ levels in VSMC with mtCaMKIIN expression compared with control-infected cells based on Ca 2+ complex formation with O-Cresolphthalein ( Figure 1F ). To further interrogate the regulatory circuit between mtCaMKII and MCU, we measured mitochondrial Ca 2+ uptake in MCU −/− VSMC. Overexpression of mitochondria-targeted CaMKII in WT VSMC was sufficient to augment PDGF-induced mitochondrial matrix Ca 2+ uptake ( Figure 1G ; Figure IF in the onlineonly Data Supplement). MCU was necessary for the effect because the Ca 2+ influx was completely abrogated in MCU −/− VSMC with mtCaMKII overexpression ( Figure 1G ). These data further support the presence of a feed-forward mtCaM-KII and MCU. To determine whether other agonists that also increase cytoplasmic Ca 2+ levels have an effect on CaMKII activation in mitochondria, we confirmed our findings using histamine stimulation. Specifically, histamine promoted CaMKII phosphorylation in mitoplasts ( Figure IG in the online-only Data Supplement), and treatment with mtCaMKIIN blunted mitochondrial Ca 2+ uptake ( Figure IH in the online-only Data Supplement). These data support that mitochondrial CaMKII activation is a general mechanism in mitochondrial Ca 2+ uptake.
Inhibition of Mitochondrial Ca 2+ Uptake Prevents VSMC Migration
We next tested whether inhibition of mitochondrial CaMKII is sufficient to alter VSMC phenotypes. mtCaMKIIN had no significant effect on cell counts after agonist stimulation ( Figure IIA in the online-only Data Supplement), whereas VSMC migration was profoundly inhibited by mtCaMKIIN in Boyden chamber migration (Figure 2A ) or wounding assays ( Figure 2B ). These findings were confirmed using siRNAmediated MCU silencing ( Figure IIB and IIC in the onlineonly Data Supplement).
To overcome the limitations of conventional migration assays, we developed a novel high-throughput scratch wound migration assay with semiautomated data analysis ( Figure IIIA in the online-only Data Supplement). mtCaMKIIN blocked PDGF-induced VSMC migration in a dose-dependent manner at 24 hours after scratch wound in the presence of a proliferation inhibitor ( Figure 2C and 2D ). Of note, mtCaMKII overexpression in WT VSMC moderately increased VSMC migration ( Figure 2E ).
As anticipated, PDGF-induced migration of VSMC from MCU −/− mice was significantly impaired using the highthroughput scratch wound migration assay ( Figure 2F ). Expression of mtCaMKIIN or mtCaMKII in MCU −/− VSMC had no significant additional effect on VSMC migration ( Figure 2F ). As a separate strategy for MCU inhibition, we examined increasing concentrations of the MCU inhibitor Ru360. As expected, we observed a dose response to Ru360 (Figure IIIB in the online-only Data Supplement). Under mtCaMKII overexpression, higher doses of Ru360 were required to delay wound closure. These data support that mitochondrial Ca 2+ uptake via MCU is necessary for the action of mitochondrial CaMKII on VSMC migration.
In addition to mitochondrial Ca 2+ uptake, both mitochondrial metabolism and mitochondrial ROS production have been implicated in cell migration. We measured oxygen consumption rate, an indicator of mitochondrial respiration, after PDGF treatment and did not observe appreciable differences with expression of mtCaMKIIN ( Figure IVA in the online-only Data Supplement). Next, we tested the effect of mtCaMKII inhibition or overexpression on mitochondrial ROS generation. As anticipated, mtCaMKII promoted whereas mtCaMKIIN abolished PDGF-induced mitochondrial ROS production ( Figure IVB and IVC in the online-only Data Supplement). Treatment with the mitochondrial ROS scavenger mitoTEMPO attenuated migration in mtCaM-KII-expressing VSMC but did not alter migration in cells expressing mtCaMKIIN ( Figure IVD in the online-only Data Supplement). These data are consistent with the concept of mitochondrial Ca 2+ uptake via mtCaMKII as an upstream regulator of mitochondrial ROS production.
Mitochondrial CaMKII Inhibition Blocks Mitochondrial Translocation Toward the Leading Edge
Studies in nonvascular cells demonstrate that mitochondrial translocation to the leading edge is required for cell migration. 7, 9, 10 In growth-arrested VSMC, mitochondria were predominantly localized in the perinuclear area ( Figure 3A) . PDGF treatment of WT VSMC for 6 to 12 hours after scratch wound induced mitochondrial translocation to the anterior edge (Figure 3A and 3B; Figure V in the online-only Data Supplement), providing evidence that mitochondrial mobility occurs in migrating VSMC. In contrast, mtCaMKIIN significantly inhibited the PDGF-induced mitochondrial redistribution at 6 to 24 hours ( Figure 3C ). This effect was phenocopied in MCU −/− VSMC or by Ru360 ( Figure 3C ). Although we found that mtCaMKIIN reduced mitochondrial ROS production, treatment of WT VSMC with mitoTEMPO had no effect on redistribution of mitochondria to the leading edge ( Figure 3C ). We also tested whether acute MCU inhibition with Ru360 could arrest translocating mitochondria in migrating WT VSMC. Indeed, when Ru360 was added at 6 hours after initiation of migration with PDGF, further mitochondrial redistribution was prevented ( Figure VI in the onlineonly Data Supplement). Together, these data suggest that inhibition of mitochondrial Ca 2+ uptake arrests mitochondrial translocation.
To provide direct experimental evidence that mitochondrial translocation is Ca 2+ -dependent, we expressed WT MCU and the MCU S92A mutant with decreased mitochondrial Ca 2+ influx in MCU −/− VSMC. Whereas WT MCU recovered VSMC migration and mitochondrial translocation to the leading edge, MCU mutant S92A did not, confirming that mitochondrial mobility depends on mitochondrial matrix Ca 2+ uptake ( Figure 3D and 3E ).
Miro-1 Is Required for mtCaMKII-Mediated Active Mitochondrial Translocation in VSMC
Mitochondria rely on intact cytoskeletal proteins to efficiently traffic throughout the cell. We tested whether mitochondrial mobility in migrating cells is an active process or whether it passively follows cell movement. We treated cells with either a microtubule or an actin inhibitor, both of which arrest cell migration. 34, 35 Only the microtubule inhibitor, nocodazole, prevented mitochondrial mobility to the leading edge ( Figure 4A ), suggesting that mitochondrial translocation in migrating cells is an active process that is selectively regulated by microtubule dynamics. In addition, PDGF treatment of contact-inhibited, confluent VSMC promoted redistribution of mitochondria away from the nucleus to the cell periphery ( Figure VIIA in the online-only Data Supplement), further substantiating that mitochondrial mobility is not a passive event.
Precedence for active mitochondrial motility comes from studies in neurons that identified the outer mitochondrial membrane GTPase Miro-1 as a coordinator of mitochondrial translocation along microtubules. 36 On Ca 2+ binding to the 2 EF hands of Miro-1, mitochondria and microtubules dissociate, which induces mitochondrial arrest. Thus, we isolated aortic VSMC from Miro-1 fl/fl mice and induced Miro-1 deletion by Cre recombination (Miro-1 −/− , Figure 4B ). In Miro-1 −/− VSMC, we detected mitochondrial arrest and strongly impaired VSMC migration in the presence of PDGF (Figure 4C through 4E) . Overexpression of mtCaMKII or mtCaMKIIN had no effect on mitochondrial translocation or VSMC migration in Miro-1 −/− VSMC. Similar results were obtained by overexpressing wild-type MCU or a dominant negative mutant that decreases the Ca 2+ influx 37 in Miro-1 −/− VSMCs ( Figure VIIB and VIID in the online-only Data Supplement). These data demonstrate that in VSMC, Miro-1 is necessary for migration and mitochondrial translocation to the leading edge. Mitochondrial mobility is abrogated by increases in local peri-mitochondrial Ca 2+ levels. 36 Because we observed a significant reduction in mitochondrial Ca 2+ uptake with MCU or mtCaMKII inhibition, we examined their impact on cytosolic Ca 2+ transients using the ratiometric indicator Fura-2 acetoxymethyl ester. Expression of mtCaMKIIN did not alter baseline cytosolic Ca 2+ levels (data not shown). Whereas total cytosolic Ca 2+ levels were transiently increased in control-infected cells after PDGF treatment, the decay of the cytosolic Ca 2+ signal was significantly prolonged under mtCaMKII inhibition, as evidenced by greater τ, residual amplitude, and area under the curve ( Figure 4F ). Together with the data in Figure 1 , these findings suggest that mtCaMKII inhibition prevents mitochondrial matrix Ca 2+ uptake and thereby prolongs the PDGF-induced transient increases in total cytosolic Ca 2+ . We posit that the perturbed cytosolic Ca 2+ transients by mtCaMKII inhibition disrupt Miro-1-dependent mitochondrial translocation toward the leading edge and arrest migration of VSMC.
Because VSMC with small, fragmented mitochondria are reported to have a higher propensity to migrate, 4 we assessed mitochondrial morphology. 38 In accordance with published evidence, 39 PDGF induced mitochondrial fission in control-infected VSMC ( Figure VIII in the online-only Data Supplement). With mtCaMKII inhibition, mitochondria were fragmented at baseline without further change in morphology with PDGF.
Mitochondrial CaMKII-Dependent Mitochondrial Translocation Is Necessary for FA Dynamics
Mitochondria provide the energy source for dynamic FA turnover at the leading edge, which is necessary for cell migration. 10, 40 Because mtCaMKIIN prevented mitochondrial translocation to the leading edge, we next interrogated the effect of mtCaMKII inhibition on FA dynamics. We first assessed FA turnover by time-lapse imaging after scratch wounding and PDGF treatment. Here, mtCaM-KIIN prevented the dynamic changes in FA redistribution observed in control-infected VSMC after 90 minutes ( Figure 5A ). We also assessed FA size as a surrogate for FA turnover because FA size predicts cell migration. 41 In migrating VSMC, FA size was decreased after PDGF treatment ( Figure 5B) . Conversely, mtCaMKIIN-expressing VSMCs exhibited large, stable FA, suggesting that mtCaM-KII inhibition promotes static FA associated with reduced cell migration.
In addition, we analyzed phosphorylation of FAK (focal adhesion kinase) at Y577 as a marker for FA activity. 42 Compared with control-infected cells, the phosphorylation was reduced in VSMC expressing mtCaMKIIN ( Figure 5C ). Myosin light chain inserts at the vicinity of FA and is phosphorylated to coordinate forward migration forces. 43 Accordingly, colocalization of phosphorylated myosin light chain to FA was reduced in VSMC expressing mtCaMKIIN compared with controls ( Figure IX in the online-only Data Supplement). These data suggest that, under mtCaMKII inhibition, reduced localization of mitochondria to the leading edge depletes the energy source necessary for dynamic FA turnover.
Mitochondrial CaMKII Inhibition Ameliorates Neointimal Hyperplasia in an In Vivo Model of Endothelial Injury
To test whether mtCaMKII inhibition reduces neointimal hyperplasia in vivo, we engineered a novel transgenic mouse model with inducible, smooth muscle-specific mtCaMKIIN expression (termed SM-mtCaMKIIN mice; Figure XA in the online-only Data Supplement). We confirmed robust transgene expression by quantitative real-time polymerase chain reaction and immunofluorescence of mtCaMKIIN in the carotid media after tamoxifen-induced Cre activation ( Figure XB in the online-only Data Supplement; Figure 6A ). Immunoblots of cytosolic and mitochondrial fractions confirmed the presence of the transgene predominantly in mitochondria ( Figure 6B ). Functional mtCaMKII inhibition was confirmed by a decrease in mitochondrial Ca 2+ concentration ( Figure 6C ). Next, we performed vascular injury by endothelial denudation of the left common carotid artery. On day 28 after endothelial injury, the neointimal area in SM-mtCaMKIIN mice was significantly reduced compared with littermate controls ( Figure 6D ; Figure XE in the online-only Data Supplement). In uninjured right carotid arteries, there was no apparent difference in arterial morphology with mtCaMKIIN expression ( Figure 6D) .
To examine the translational potential of our findings, we performed coimmunostaining for CaMKII and a mitochondrial marker in human coronary arteries from autopsy samples , mobility, and VSMC migration. mtCaMKII regulates a feed-forward circuit that promotes mitochondrial Ca 2+ uptake. Inhibition of mtCaMKII leads to decreased mitochondrial Ca 2+ uptake, leading to decreased Ca 2+ clearance in the cytosol and mitochondrial arrest. This prevents mitochondria from translocating to focal adhesions, thus inhibiting VSMC migration and neointima formation. 
Discussion
The goal of this study was to identify key regulators of mitochondrial function that contribute to VSMC migration and neointimal hyperplasia. First, we demonstrate that CaMKII resides in mitoplasts of VSMC and was activated by PDGF. Activation of CaMKII in mitochondria was abrogated when MCU was deleted. Inhibition of mtCaMKII lowered the phosphorylation of MCU at S92, a site that is crucial for mitochondrial Ca 2+ uptake by MCU activity. MtCaMKII inhibition blocked mitochondrial translocation to the leading edge and VSMC migration. These effects were recapitulated by deletion of MCU. Overexpression of WT MCU but not of the MCU mutant S92A in MCU −/− VSMC recovered mitochondrial translocation and migration, suggesting that the effects of MCU or mtCaMKII on these phenotypes are caused by altered mitochondrial Ca 2+ uptake. Ca 2+ -dependent mitochondrial mobility is coordinated by Miro-1, an outer mitochondrial membrane GTPase. In agreement, in Miro-1 −/− VSMC, mitochondrial mobility and migration were abolished, establishing Miro-1 as a key regulator of mitochondrial function in VSMC. mtCaMKII overexpression or inhibition did not have any effect on Miro-1 −/− VSMC, suggesting that Miro-1 mediates the effect of mtCaMKII on mitochondrial mobility and migration. Consistent with the notion that increased Ca 2+ levels arrest mitochondria, Ca 2+ clearance from the cytosol was delayed with mtCaMKII inhibition. Moreover, mtCaMKII inhibition led to impaired FA turnover and phosphorylation of cytoskeletal proteins necessary for coordinated anterior cell movement. In agreement with in vitro findings, transgenic CaMKII inhibition selectively in mitochondria of VSMC significantly reduced neointimal hyperplasia after endothelial vascular injury. Together, these data provide key mechanistic insight into how mitochondrial function regulates VSMC migration and neointimal hyperplasia: mtCaMKII controls mitochondrial Ca 2+ uptake through activation of MCU and is necessary for mitochondrial translocation to the leading edge of migrating VSMC where mitochondria support FA and cytoskeletal remodeling ( Figure 6E) .
Several other studies support that mitochondrial Ca 2+ uptake regulates cell migration. 17 For example, MCU inhibition or knockdown halts cell migration of cancer cells, whereas increased expression of MCU correlates with an invasive phenotype. 16 Our data in VSMC are in line with these observations and provide further insight into how regulation of mitochondrial Ca 2 uptake is regulated and affects VSMC migration. CaMKII has been detected in the mitochondrial matrix of cardiac myocytes and reported to blunt mitochondrial matrix Ca 2+ uptake. 20 Here, we provide further mechanistic evidence for the actions of mtCaMKII in mitochondria; phosphorylation of MCU at S92, a validated strong regulatory site for MCU activity, 15 was reduced when mtCaMKII activity is inhibited. CaMKII activation requires an initial binding of calcified calmodulin that is abundant in the mitochondrial matrix. 44 Accordingly, mtCaMKII activation was abrogated when MCU was deleted or inhibited. Moreover, mtCaMKII inhibition prevented further mitochondrial Ca 2+ uptake, suggesting a feed-forward circuit in which initial mitochondrial Ca 2+ influx via MCU is required for mtCaMKII activation, which in turn controls MCU activity via phosphorylation at S92. mtCaMKII thereby drives further mitochondrial Ca 2+ uptake. Alternatively, mtCaMKII may regulate Ca 2+ uptake via phosphorylation of other sites on MCU, such as S57 as proposed by a recent study, by phosphorylation of MCU regulators MICU1 or EMRE (essential MCU regulator), 14, 45 or potentially by activating Ca 2+ influx via another Ca 2+ channel, such as the mitochondrial RyR receptor. 46 Previous studies reported that dynamic mitochondrial fission and fusion are required for VSMC migration. In particular, migration was abolished when a dominant negative mutant of Drp-1, a master regulator of mitochondrial fission, was expressed in VSMC. On the basis of this study and other reports, it has been proposed that VSMC with small, fragmented mitochondria have a higher propensity to migrate. 4 However, with mtCaMKII inhibition, mitochondria were fragmented at baseline without further change in morphology with PDGF, implying that mitochondrial size is not a major determinant of mobility when mitochondrial Ca 2+ uptake is altered. Our study provides novel mechanistic insight by defining mitochondrial mobility as a function of Ca 2+ levels and a prerequisite for VSMC migration and likely neointimal hyperplasia.
Mitochondrial mobility is arrested in microdomains of high Ca 2+ concentrations, as may occur in the vicinity of mitochondrial/ER convergence zones when the mitochondrial Ca 2+ uptake is impaired with MCU or mtCaMKII inhibition. In subcellular domains of high Ca 2+ concentrations in neurons, 19, 36 Ca 2+ binding to the EF hands of the Rho-GTPase Miro-1 induces the dissociation of mitochondria from microtubules, followed by mitochondrial arrest. Our findings are in agreement with these data and demonstrate that mitochondrial translocation in VSMC is an active process and controlled by Miro-1. Alternatively, tethering of mitochondria to actin filaments via myosin V, which is induced by locally increased Ca 2+ levels, has been implicated to halt mobile mitochondria. 47 However, our data do not support this mechanism because we detected mitochondrial redistribution to the leading edge despite disruption of the actin cytoskeleton. Once at the leading edge, mitochondria cluster in the vicinity of FA, to meet the significant energy demands for FA turnover and cytoskeletal remodeling in migrating cells. 7, 10, 11, 40 Consistent with this mechanism, we detected reduced FA activity under mtCaM-KII inhibition.
CaMKII is well accepted to be present and active in the cytosol and nucleus where it fulfills distinct roles in the regulation of transcriptional events 48, 49 substrate phosphorylation of a wide array of signaling mediators. 50 Different approaches to globally block intracellular CaMKII activity have revealed its regulatory function in cell migration. Using a mitochondria-targeted CaMKII inhibitory peptide, we discovered that the effects of CaMKII on migration are due, at least in part, to its actions in mitochondria. Previous data suggest that the spatial and functional specificity in CaMKII activation is
